Internal Medicine, Endocrinology, Diabetes, & Metabolism · Lyndhurst, NJ
NPI
1740488402
Since 2007
Specialty
Internal Medicine, Endocrinology, Diabetes, & Metabolism
Code 207RE0101X
Group practices
2
Medicare group memberships
Hospitals
3
Hospital affiliations
612 Rutherford Ave
Lyndhurst, NJ, 07071
Phone (201) 460-0063
Groups this clinician bills Medicare through
Medicare paid, 2024
$200K
3,017 services
Medicare patients, 2024
801
Average age 71
Drug cost, 2024
$3.9M
9,316 prescriptions
Company payments, 2025
$57K
From 37 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Stanislav Goykhman was code 99214 (office e&m - established), 1,733 times for 707 patients. In total Stanislav Goykhman billed 3,017 services in 24 codes, and Medicare paid $200K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2018-03-17.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| 99214 Office E&M - Established | Office | 1,733 | 707 | $91.04 | $158K |
| 95251 Test - Miscellaneous | Office | 235 | 107 | $25.31 | $5,947 |
| 82962 Clinical Chemistry | Office | 130 | 72 | $3.05 | $397 |
| 99213 Office E&M - Established | Office | 109 | 90 | $64.14 | $6,992 |
| 99204 Office E&M - New | Office | 100 | 100 | $118.40 | $12K |
| 82947 Clinical Chemistry | Office | 52 | 44 | $3.70 | $193 |
| 96372 Injection Administration | Office | 32 | 22 | $9.58 | $307 |
| 10005 Other Organ Systems | Office | 18 | 16 | $105.06 | $1,891 |
By year: 2022 $212K for 4,350 services; 2023 $200K for 3,361 services; 2024 $200K for 3,017 services.
Lab tests billed to Medicare, 2024
| Test code | Tests | Patients | Paid per test | Medicare paid |
|---|---|---|---|---|
| 82962 Clinical Chemistry | 130 | 72 | $3.05 | $397 |
| 82947 Clinical Chemistry | 52 | 44 | $3.70 | $193 |
Medicare prescription drug claims, 2024
In 2024, the drug Stanislav Goykhman prescribed most often to Medicare patients was Levothyroxine Sodium, with 882 prescriptions and refills. In total Stanislav Goykhman wrote 9,316 Medicare prescriptions that cost $3.9M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Levothyroxine Sodium Generic | 882 | 2,433 | 257 | $8,741 |
| Metformin Hcl Generic | 631 | 1,660 | 202 | $5,193 |
| Atorvastatin Calcium Generic | 572 | 1,498 | 204 | $7,184 |
| Glimepiride Generic | 454 | 1,240 | 143 | $6,376 |
| Jardiance Empagliflozin | 384 | 823 | 114 | $468K |
| Ozempic Semaglutide | 371 | 667 | 103 | $605K |
| Rosuvastatin Calcium Generic | 307 | 806 | 118 | $5,051 |
| Mounjaro Tirzepatide | 237 | 362 | 55 | $384K |
| Lantus Solostar Insulin Glargine,hum.Rec.Anlog | 220 | 434 | 70 | $27K |
| Farxiga Dapagliflozin Propanediol | 191 | 408 | 65 | $227K |
| Lisinopril Generic | 187 | 455 | 56 | $1,105 |
| Nano 2nd Gen Pen Needle Pen Needle, Diabetic | 184 | 432 | 73 | $22K |
| Metformin Hcl Er Metformin Hcl | 178 | 456 | 57 | $1,760 |
| Glipizide Generic | 158 | 411 | 51 | $2,454 |
| Trulicity Dulaglutide | 155 | 251 | 43 | $243K |
Brand drugs: 3,938 claims; generic drugs: 4,804 claims.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Stanislav Goykhman $57K ($57K in general payments such as food, travel and fees) from 37 companies. The largest payer was Lilly USA, LLC with $26K.
| Company | Payments | Amount |
|---|---|---|
| Lilly USA, LLC LLY | 63 | $26K |
| Dexcom, Inc. DXCM | 17 | $17K |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 20 | $11K |
| Amgen Inc. AMGN | 16 | $363 |
| Corcept Therapeutics CORT | 21 | $357 |
| Novo Nordisk Inc NVO | 15 | $305 |
| Mannkind Corporation MNKD | 13 | $225 |
| Ascendis Pharma Endocrinology Inc ASND | 5 | $183 |
| Abbvie Inc. ABBV | 17 | $168 |
| Sanofi-Aventis U.S. LLC SNY | 10 | $157 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.